Skye Bioscience Inc (SKYE)

$0.93 -0.08 (-7.92%)
Market Cap 32.38M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,391,400
Avg Vol 407,056
Day's Range N/A - N/A
Shares Out 32.06M
Stochastic %K 8%
Beta 2.68
Analysts Strong Sell
Price Target $8.71

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
MissionaryTrader
MissionaryTrader Feb. 3 at 12:31 AM
$SKYE https://d1io3yog0oux5.cloudfront.net/_761418a0eafb14a514d981d71452b331/skyebioscience/db/854/9048/pdf/260202_Skye_Corporate_Presentation.pdf
0 · Reply
MissionaryTrader
MissionaryTrader Feb. 3 at 12:02 AM
$SKYE Skye’s response to my question below, part 1 Hi Jack, Thank you for the note, the timeline looks confusing because there are two different “extension” readouts. Interim 52-week combination extension data (blinded): this is the semaglutide ± nimacimab continuation, and that is what we reported in today’s press release / Q1 update. Full extension dataset (including the 13-week off-therapy follow-up) and the 300 mg monotherapy extension: this requires the last participants to complete both treatment and the follow-up period, which is why the expected timing is Q3.
0 · Reply
MissionaryTrader
MissionaryTrader Feb. 3 at 12:00 AM
$SKYE part 2 of Skye’s response The 300 mg monotherapy extension started later (and is also blinded), so its readout is driven by when those participants reach 26 weeks and complete the subsequent follow-up. On dose: 300 mg was added primarily to provide an additional PK datapoint and refine the exposure–response framework for nimacimab. As outlined in our dosing rationale, our translational modeling suggests that higher exposures (e.g., 600 mg+) may be required to consistently achieve the peripheral tissue engagement we are targeting. In the presentation posted online today there is a section 2.1 that covers the details around dosing rationale and slide 31 is helpful to this earlier point of concentration of nimacimab to achieve peripheral tissue engagement.
0 · Reply
bkarthikkannan
bkarthikkannan Feb. 2 at 10:19 PM
$SKYE 5k stocks averaged $2. Hoping $3 in 3 months
0 · Reply
MissionaryTrader
MissionaryTrader Feb. 2 at 5:10 PM
$SKYE I’m confused by the timeline for clinical data release. Are we still expecting the mono therapy results this quarter and will there be additional combo results for the 13 weeks? ”Patients who completed 26 weeks of treatment in the primary phase of the study were eligible to enroll in a 26-week extension for a potential full treatment duration of 52 weeks with a 13-week follow-up period. In the combination arms, patients will continue with blinded treatment with nimacimab or placebo and will continue receiving semaglutide (Wegovy®). Patients in the monotherapy arm will receive nimacimab 300 mg during the extension. Enrollment for the extension is complete. Skye expects to report data from the extension study in Q1 2026.”
1 · Reply
Babybillysbiblebonker
Babybillysbiblebonker Feb. 2 at 2:08 PM
$SKYE Weight loss promise and potential at this price means way too cheap. THis should be at least 5
0 · Reply
YazzJr
YazzJr Feb. 2 at 1:38 PM
$SKYE Pretty solid news from SKYE at their recent conference. If they can parlay that with good 300mg results this month that would probably put them back into the buyout conversation.
1 · Reply
SkyeBioscience
SkyeBioscience Feb. 2 at 1:13 PM
Today, $SKYE reported positive interim CBeyond™ Phase 2a extension results evaluating nimacimab in combination with semaglutide, demonstrating 22.3% average total weight loss at 52 weeks, with no plateau observed and a favorable safety and tolerability profile. The data also showed reduced weight regain during treatment interruption, supporting the potential durability of peripheral CB1 inhibition when combined with GLP-1 therapy. These results further reinforce nimacimab’s differentiated profile and support our strategy to advance combination approaches in obesity and metabolic disease. Read the full release: https://ir.skyebioscience.com/news-releases/detail/253/skye-reports-positive-cbeyond-phase-2a-extension-interim-study-results-for-nimacimab-in-combination-with-semaglutide #Biotech #Obesity #ClinicalDevelopment
0 · Reply
Jangalang
Jangalang Feb. 2 at 12:30 PM
$SKYE … We all been SCAMMED.
0 · Reply
Jangalang
Jangalang Feb. 2 at 12:29 PM
$SKYE … Top five worst investments of my life.
0 · Reply
Latest News on SKYE
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Feb 2, 2026, 1:26 PM EST - 13 hours ago

Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

Feb 2, 2026, 7:00 AM EST - 20 hours ago

Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Jan 29, 2026, 7:00 AM EST - 4 days ago

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

Skye Bioscience to Present Poster at Keystone Obesity Conference

Jan 21, 2026, 7:00 AM EST - 12 days ago

Skye Bioscience to Present Poster at Keystone Obesity Conference

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 16, 2026, 10:31 AM EST - 17 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 14, 2026, 10:31 AM EST - 19 days ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 12, 2026, 6:11 PM EST - 21 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Skye Provides 2026 Corporate Outlook

Jan 12, 2026, 7:00 AM EST - 21 days ago

Skye Provides 2026 Corporate Outlook

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Jan 9, 2026, 9:45 AM EST - 24 days ago

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

Jan 5, 2026, 7:00 AM EST - 4 weeks ago

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

HALO

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Dec 19, 2025, 2:56 PM EST - 6 weeks ago

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Dec 8, 2025, 7:11 AM EST - 2 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 24, 2025, 7:00 AM EST - 2 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:41 PM EST - 3 months ago

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 4:01 PM EST - 3 months ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:05 AM EST - 3 months ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Nov 5, 2025, 7:00 AM EST - 3 months ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Oct 28, 2025, 8:00 AM EDT - 3 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

Skye Bioscience, Inc. - Special Call

Oct 6, 2025, 2:25 PM EDT - 4 months ago

Skye Bioscience, Inc. - Special Call

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Oct 6, 2025, 1:09 PM EDT - 4 months ago

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Oct 6, 2025, 10:39 AM EDT - 4 months ago

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:09 AM EDT - 4 months ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Oct 6, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Oct 1, 2025, 10:45 AM EDT - 4 months ago

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Could This New Drug Be The Safer Way To Fight Obesity?

Sep 19, 2025, 2:19 PM EDT - 4 months ago

Could This New Drug Be The Safer Way To Fight Obesity?

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 19, 2025, 7:00 AM EDT - 4 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 9:45 AM EDT - 5 months ago

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 5, 2025, 1:35 PM EDT - 5 months ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Sep 5, 2025, 1:30 AM EDT - 5 months ago

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 4, 2025, 7:00 AM EDT - 5 months ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Sep 2, 2025, 7:00 AM EDT - 5 months ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 27, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 21, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:36 PM EDT - 6 months ago

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

MissionaryTrader
MissionaryTrader Feb. 3 at 12:31 AM
$SKYE https://d1io3yog0oux5.cloudfront.net/_761418a0eafb14a514d981d71452b331/skyebioscience/db/854/9048/pdf/260202_Skye_Corporate_Presentation.pdf
0 · Reply
MissionaryTrader
MissionaryTrader Feb. 3 at 12:02 AM
$SKYE Skye’s response to my question below, part 1 Hi Jack, Thank you for the note, the timeline looks confusing because there are two different “extension” readouts. Interim 52-week combination extension data (blinded): this is the semaglutide ± nimacimab continuation, and that is what we reported in today’s press release / Q1 update. Full extension dataset (including the 13-week off-therapy follow-up) and the 300 mg monotherapy extension: this requires the last participants to complete both treatment and the follow-up period, which is why the expected timing is Q3.
0 · Reply
MissionaryTrader
MissionaryTrader Feb. 3 at 12:00 AM
$SKYE part 2 of Skye’s response The 300 mg monotherapy extension started later (and is also blinded), so its readout is driven by when those participants reach 26 weeks and complete the subsequent follow-up. On dose: 300 mg was added primarily to provide an additional PK datapoint and refine the exposure–response framework for nimacimab. As outlined in our dosing rationale, our translational modeling suggests that higher exposures (e.g., 600 mg+) may be required to consistently achieve the peripheral tissue engagement we are targeting. In the presentation posted online today there is a section 2.1 that covers the details around dosing rationale and slide 31 is helpful to this earlier point of concentration of nimacimab to achieve peripheral tissue engagement.
0 · Reply
bkarthikkannan
bkarthikkannan Feb. 2 at 10:19 PM
$SKYE 5k stocks averaged $2. Hoping $3 in 3 months
0 · Reply
MissionaryTrader
MissionaryTrader Feb. 2 at 5:10 PM
$SKYE I’m confused by the timeline for clinical data release. Are we still expecting the mono therapy results this quarter and will there be additional combo results for the 13 weeks? ”Patients who completed 26 weeks of treatment in the primary phase of the study were eligible to enroll in a 26-week extension for a potential full treatment duration of 52 weeks with a 13-week follow-up period. In the combination arms, patients will continue with blinded treatment with nimacimab or placebo and will continue receiving semaglutide (Wegovy®). Patients in the monotherapy arm will receive nimacimab 300 mg during the extension. Enrollment for the extension is complete. Skye expects to report data from the extension study in Q1 2026.”
1 · Reply
Babybillysbiblebonker
Babybillysbiblebonker Feb. 2 at 2:08 PM
$SKYE Weight loss promise and potential at this price means way too cheap. THis should be at least 5
0 · Reply
YazzJr
YazzJr Feb. 2 at 1:38 PM
$SKYE Pretty solid news from SKYE at their recent conference. If they can parlay that with good 300mg results this month that would probably put them back into the buyout conversation.
1 · Reply
SkyeBioscience
SkyeBioscience Feb. 2 at 1:13 PM
Today, $SKYE reported positive interim CBeyond™ Phase 2a extension results evaluating nimacimab in combination with semaglutide, demonstrating 22.3% average total weight loss at 52 weeks, with no plateau observed and a favorable safety and tolerability profile. The data also showed reduced weight regain during treatment interruption, supporting the potential durability of peripheral CB1 inhibition when combined with GLP-1 therapy. These results further reinforce nimacimab’s differentiated profile and support our strategy to advance combination approaches in obesity and metabolic disease. Read the full release: https://ir.skyebioscience.com/news-releases/detail/253/skye-reports-positive-cbeyond-phase-2a-extension-interim-study-results-for-nimacimab-in-combination-with-semaglutide #Biotech #Obesity #ClinicalDevelopment
0 · Reply
Jangalang
Jangalang Feb. 2 at 12:30 PM
$SKYE … We all been SCAMMED.
0 · Reply
Jangalang
Jangalang Feb. 2 at 12:29 PM
$SKYE … Top five worst investments of my life.
0 · Reply
cat64
cat64 Feb. 2 at 12:16 PM
$SKYE Positive trial news today!
0 · Reply
SkyeBioscience
SkyeBioscience Jan. 29 at 4:52 PM
$SKYE presented new data at the Keystone Symposium on Obesity, highlighting key attributes of nimacimab, our peripherally restricted CB1 inhibitor antibody. View the poster to learn how nimacimab’s biodistribution supports metabolic activity while limiting central exposure: https://skyebioscience.com/keystone-2026-obesity-CB1-inhibitor/
0 · Reply
Fellforit
Fellforit Jan. 28 at 5:39 PM
$SKYE still above $1
0 · Reply
EdgeUnknown
EdgeUnknown Jan. 25 at 8:55 PM
Next Week Playbook $AQST , $SKYE , $SLXN, $HCTI and $BCAB
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 23 at 3:25 PM
$SKYE RSI: 59.49, MACD: -0.0225 Vol: 0.11, MA20: 0.94, MA50: 1.10 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SkyeBioscience
SkyeBioscience Jan. 21 at 6:53 PM
$SKYE Bioscience will be presenting a poster at the Keystone Obesity Conference. The presentation highlights ongoing scientific work supporting our focus in metabolic disease. Read the press release here: https://ir.skyebioscience.com/news-releases/detail/251/skye-bioscience-to-present-poster-at-keystone-obesity-conference
0 · Reply
Fellforit
Fellforit Jan. 20 at 9:12 PM
$SKYE appreciate the block..you keep blocking and i'll keep running up my portfolio..just stating facts and trying to help--i go all the way back to listening to dhillon's bullshit since his appointment
0 · Reply
Fellforit
Fellforit Jan. 19 at 12:15 AM
$SKYE on launch pad--for the millonth time..what you think @MissionaryTrader??
1 · Reply
Jangalang
Jangalang Jan. 17 at 6:21 AM
$SKYE … Absolute Garbage. 🗑️
1 · Reply
Fellforit
Fellforit Jan. 16 at 7:44 PM
$SKYE could be a runaway breakout!!
1 · Reply
zipperson
zipperson Jan. 15 at 6:51 PM
$SKYE it’s dying…
0 · Reply
S2K_TP
S2K_TP Jan. 14 at 3:33 PM
$SKYE long swing. 2+ on deck
1 · Reply